Table 4 Ongoing phase 2 anti-tau therapy trials
From: Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Agent | Company | Synonyms | Therapeutic purpose | ClinicalTrials.gov identifier | Status |
|---|---|---|---|---|---|
ACI-35 | AC Immune SA | Tau Morphomer | Immunotherapy (passive) | NCT04445831 | Active, not recruiting |
Bepranemab | Hoffmann-La Roche, UCB S.A | UCB0107 | Immunotherapy (passive) | NCT04867616 | Active, not recruiting |
BIIB080(CELIA) | Biogen, IONIS Pharmaceuticals | IONIS-MAPTRx, ISIS 814907 | Tau DNA/RNA-based | NCT05399888 | Recruiting |
E2814 (DIAN-TU-001 (E2814)) | Eisai | Immunotherapy (passive) | NCT05269394 | Recruiting | |
JNJ-63733657 (AUTONOMY) | Janssen | Immunotherapy (passive) | NCT04619420 | Recruiting | |
LY3372689 | Eli Lilly & Co | Tau small molecule | NCT05063539 | Active, not recruiting |